Cangrelor compared with clopidogrel improves efficiency without incre…
INCIDENCE AND PREDICTORS OF STENT THROMBOSIS AFTER PCI IN ACUTE MYOCARDIAL INFARCTION | Journal of the American College of Cardiology
Novel Antiplatelet Therapies for Atherothrombotic Diseases | Arteriosclerosis, Thrombosis, and Vascular Biology
Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial. | Request PDF
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study - Tamez - 2018 - Catheterization and Cardiovascular Interventions - Wiley Online Library
Antiplatelet Drugs in the Management of Coronary Artery Disease - ScienceDirect
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study - Tamez - 2018 - Catheterization and Cardiovascular Interventions - Wiley Online Library
Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent - ScienceDirect
Intra-Procedural Stent Thrombosis: A New Risk Factor for Adverse Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes | JACC: Cardiovascular Interventions
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
Full text] Prevention of stent thrombosis: challenges and solutions | VHRM
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks - ScienceDirect
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary ...
Cathlab & Cardiovascular News
PDF) The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum
Rapamune (Sirolimus) Market Share, Size 2020 By Industry Future Demand, Global Research, Top Leading Players, Developing Trends, Region Forecast To 2026 | News Break
Cardiovascular Medicine - Current trends in dual antiplatelet therapy: a 2017 update
Stent Thrombosis: A Clinical Perspective | JACC: Cardiovascular Interventions
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
PCI for STEMI - The Cardiology Advisor
PDF) Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX
2014 ESC/EACTS Guidelines on myocardial revascularization – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
Antiplatelet Drugs in the Management of Coronary Artery Disease - ScienceDirect
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar
Complications of Coronary Artery Interventions: Overview | SpringerLink
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study | Semantic Scholar